

## **RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022**

Milan, 3<sup>rd</sup> May 2022 – Please be informed that the summary report of the voting results related to the resolutions approved by the Ordinary General Meeting of the Shareholders on 29<sup>th</sup> April 2022, pursuant to article 125-quater of the Legislative Decree 58/98, is available to the public on the Company's website ([www.recordati.it](http://www.recordati.it), in the area "Investors", section "Shareholders' Meetings") and on the "1info" storage mechanism ([www.1info.it](http://www.1info.it)).

***Recordati** (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was €1,580.1 million, operating income was €490.2 million and net income was €386.0 million.*

Further information:

Recordati website: [www.recordati.it](http://www.recordati.it)

Investor Relations

Federica De Medici

(39) 02 48787146

email: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Press Office

Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: [recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered office

VIA M. CIVITALI, 1

20148 MILAN, ITALY

TEL. +39 0248787.1

FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up

BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI

00748210150

TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.à.r.l